Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xenon Achieves Genentech Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Xenon Achieves Genentech Milestone

Identifies pain target using Extreme Genetics platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Xenon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has achieved a milestone in its pain genetics discovery collaboration with Genentech, triggering an undisclosed milestone payment. The companies have successfully discovered and identified a novel pain target leveraging Xenon’s Extreme Genetics platform based on the study of rare phenotypes of individuals who have either an inability to perceive pain or have spontaneous severe pain.

“We are proud of our progress in our discovery collaboration with Genentech, which underscores the potential of our Extreme Genetics discovery platform and our ability to identify novel targets and pathways that may play a causal role in the sensation of pain,” said Dr. Simon Pimstone, president and chief executive officer of Xenon. “There is a critical need for non-opioid alternatives for patients with chronic pain. We look forward to working further with Genentech to discover additional targets that could yield novel therapeutics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics